Clearmind Medicine (CMND) Gains from Investment Securities (2023 - 2026)
Clearmind Medicine (CMND) posted quarterly Gains from Investment Securities of -$505000.0 for Q2 2026, up 24.03% year-over-year from -$407147.6 in Q2 2025, and down 900.61% quarter-over-quarter from -$50469.0 in Q1 2026.
Clearmind Medicine (CMND) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Clearmind Medicine's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$505000.0 for Q2 2026.
- In Q2 2026, Gains from Investment Securities rose 24.03% year-over-year to -$505000.0; the TTM figure through Apr 2026 stood at $833245.0 (up 188.52% YoY), while the FY2025 annual figure was $209196.0, changed N/A from the prior year.
- Gains from Investment Securities for Q2 2026 stood at -$505000.0, down from -$50469.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $1.5 million in Q4 2025, with the low at -$664768.0 in Q2 2025.
- The 4-year median for Gains from Investment Securities is -$147353.0 (2024), against an average of -$49561.6.
- Peak annual rise in Gains from Investment Securities reached 286.98% in 2024, while the deepest fall reached 9781.07% in 2024.
- Clearmind Medicine's Gains from Investment Securities stood at -$344002.0 in 2023, then soared by 286.98% to $643225.0 in 2024, then surged by 137.6% to $1.5 million in 2025, then tumbled by 133.04% to -$505000.0 in 2026.
- Business Quant data shows CMND's Gains from Investment Securities at -$505000.0 in Q2 2026, -$50469.0 in Q1 2026, and $1.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Clearmind Medicine | 537,435.54 | -13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -505,000.00 |
| Apr 30, 2026 | -505,000.00 |
| Jan 31, 2026 | -50,469.00 |
| Jan 31, 2026 | -50,469.00 |
| Oct 31, 2025 | 1.53 Mn |
| Oct 31, 2025 | 1.53 Mn |
| Jul 31, 2025 | -139,563.00 |
| Jul 31, 2025 | -139,563.00 |
| Apr 30, 2025 | -664,768.00 |
| Apr 30, 2025 | -664,768.00 |
| Jan 31, 2025 | -514,750.00 |
| Jan 31, 2025 | -514,750.00 |
| Jul 31, 2024 | 643,225.00 |
| Jul 31, 2024 | 643,225.00 |
| Apr 30, 2024 | -405,002.00 |
| Apr 30, 2024 | -405,002.00 |
| Jan 31, 2024 | -155,143.00 |
| Jan 31, 2024 | -155,143.00 |
| Jul 31, 2023 | -344,002.00 |
| Jul 31, 2023 | -344,002.00 |